SOUTH SAN FRANCISCO, Calif. — August 20, 2025 — Leads & Copy — Aligos Therapeutics, Inc. (Nasdaq: ALGS) has appointed Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs, effective immediately. Polo’s regulatory expertise will be crucial as Aligos advances ALG-000184 through the Phase 2 B-SUPREME study.
Dr. Polo previously served as Senior Vice President, Head of Global Regulatory Affairs at Shionogi Inc., and as Vice President, Head of Infectious Diseases, Vaccines & Global Public Health Regulatory Affairs at Johnson & Johnson, where he was involved with the COVID-19 vaccine. He holds degrees from the Complutense University of Madrid and the IESE Business School, University of Navarra.
Aligos Therapeutics is focused on developing therapies for liver and viral diseases.
Contact: Jordyn Tarazi, Vice President, Investor Relations & Corporate Communications, +1 (650) 910-0427, jtarazi@aligos.com
Media Contact: Jake Robison, Vice President, Jake.Robison@inzioevoke.com
Source: Aligos Therapeutics, Inc.
